Skip to main content

Healthcare stocks lost ground this afternoon, with the NYSE Health Care Index falling 0.5% and the SPDR Health Care Select Sector ETF (XLV) falling less than 0.1%.

The Nasdaq Biotechnology Index, however, was still climbing 0.7% in late trades.

In company news, bioAffinity Technologies (BIAF) soared nearly 19% after the noninvasive testing company released a peer-reviewed study outlining how its CyPath flow cytometry test can be used to diagnose lung cancer and other diseases of mucus and saliva in a patient’s lung.

Cross Country Healthcare (CCRN) gained 7.9% after the medical staffing firm on Wednesday announced its purchase of privately held Mint Medical Physician Staffing and Lotus Medical Staffing for an undisclosed amount and also raised its earnings forecast and revenue for the third quarter. The company increased its projected revenue for the current quarter ending Sept. 30 by $10 million on both sides of its prior guidance to a new range of $615 million to $625 million from the Capital IQ consensus that expects $610.3 million in revenue.

Exscientia (EXAI) rose 3% after the pharmaceutical company said on Tuesday evening that CEO Andrew Hopkins had purchased 26,300 of its US depository shares through a series of open market transactions at an average of $9.75 by ADS. Hopkins also owns nearly 19.1 million ordinary shares, according to the UK-based company.

Among decliners, Genfit (GNFT) was down 3% this afternoon, reversing an early morning lead of just over 1% that followed the company on Tuesday night saying the US Food and Drug Administration designated its product candidate GNS561 as an orphan drug for treatment. cholangiocarcinoma, a rare form of liver cancer mainly affecting people over the age of 50.

You might also like